Biogen

Biogen is a Cambridge biotechnology company focused on neuroscience, discovering and developing therapies for people living with serious neurological and neurodegenerative diseases. It has a leading portfolio of medicines for multiple sclerosis, introduced the first approved treatment for spinal muscular atrophy and also sells biosimilars of advanced biologic drugs. Its research pipeline extends into immunology and rare diseases, alongside programs in Alzheimer’s disease and dementia, neuromuscular and movement disorders, and ophthalmology.

One of the world’s first global biotechnology companies, Biogen was founded in 1978 by a group of scientists that included Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel laureates Walter Gilbert and Phillip Sharp. The company describes its approach as taking bold scientific risks balanced with return on investment to pursue first-in-class treatments. Its stated values are caring deeply, achieving excellence and changing lives.

What to Know

• Research areas also include neurocognitive disorders, acute neurology and pain.
• The company shares patient stories, such as people living with rare blood and skin conditions, on its website.
• Biogen operates worldwide while keeping its headquarters in Cambridge.
• It is a member of the Kendall Square Association.